Omeros misses, but Yartemlea boosts cash flow growth
Omeros reports Q3 revenue of $35.9M, missing estimates, as YARTEMLEA growth supports positive cash flow despite EU setback
- GAAP net loss widened to $57.4M, largely from a noncash derivative adjustment.
- Third-quarter non-GAAP EPS was $0.06 alongside the reported revenue results.
- YARTEMLEA net sales reached $35.9M, up 26% QoQ in second full launch quarter.
- Company generated $13.3M operating cash, second straight quarter of positive operating cash flow.
- Non-GAAP adjusted net income rose to $4.7M, despite GAAP loss from noncash convertible-note derivative.
- YARTEMLEA account base grew to 109 centers; P&T approvals at 80% of top 40.
- Outpatient and 340B use rising, driving gross-to-net to 14% and likely high-teens longer term.
- U.S. reimbursement position strengthened by NTAP and long pass-through status, supporting hospital economics versus off-label competitors.
- European expansion hit by CHMP negative opinion; compassionate-use program closed to new patients.
- Balance sheet de-risked via $30.5M principal convert repurchase, cutting debt 43% and dilution risk.
- Two new YARTEMLEA studies starting in ARDS and TA-TMA prophylaxis, plus multiple earlier-stage pipeline assets advancing.
- Management delaying formal revenue guidance until 2027; investors focused on launch durability and ex-U.S. strategy.
- Main concern: Uncertain ex-U.S. regulatory/commercial path for YARTEMLEA and sustainability of current launch ramp in a niche indication.
- Strong quarter, driven by accelerating YARTEMLEA adoption and improving underlying profitability and cash generation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.